Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PROUD-PV: Ropeginterferon alfa-2b vs. Hydroxyurea in Polycythemia Vera
NCT01949805Phase 3Completed
- Sponsor
- AOP Health
- Start
- Sep 2013
- Primary completion
- Jul 2016
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 14
01
Overview
Phase 3, randomised, open-label trial of ropeginterferon alfa-2b in polycythemia vera (PV) (2 arms), sponsored by AOP Health. Primary endpoint: Disease response rate at 12 months. Started Sep 2013; status: completed.
02
Drugs
ropeginterferon alfa-2b
03
Conditions
polycythemia vera (PV)
Beyond the preview
Go deeper on NCT01949805.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01949805.